Matthew Gline, CEO at Roivant Sciences Ltd. (ROIV), sold 8,509 shares at $3.84 ($33K) on 2022-04-25, disclosed to the SEC on 2022-04-27.
Scheduled sale ($33k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ROIV | BUY | 2025-09-18 | $50K | — | Filing → |
| ROIV | SELL | 2024-09-24 | $46.8M | — | Filing → |
| ROIV | SELL | 2022-10-27 | $170K | — | Filing → |